arXiv:2606. 03995v1 Announce Type: cross Abstract: Background: Alzheimer's disease (AD) affects over 55 million people worldwide.
arXiv:2607. 02142v1 Announce Type: cross Abstract: Alzheimers disease (AD) is a brain disorder that develops slowly and mainly affects memory, thinking, language, and daily activities.
The study presents an explainable multimodal deep‑learning framework that combines a 3D CNN for T1‑weighted MRI with a feedforward network for harmonized clinical and demographic data to diagnose Alzheimer’s disease. Using 6,479 ADNI records and 1,703 OASIS‑3 records, the authors compare various model configurations on three‑way and pairwise diagnostic tasks, finding that performance and explanations vary by task, modality, fusion strategy, and cohort. SHAP and Integrated Gradients consistently highlight the MMSE score as the most influential tabular feature, while CAM‑based explanations differ across model setups and cohorts, indicating that explainability is not a stable property under cohort shift.
arXiv:2607. 28687v1 Announce Type: cross Abstract: As populations age, cognitive decline from mild cognitive impairment (MCI) to dementia is a defining health challenge of the coming decades, yet routine assessment often misses its earliest signs.
arXiv:2606. 20037v1 Announce Type: new Abstract: Alzheimer's disease (AD) is an irreversible neurodegenerative disorder and a leading cause of death worldwide.
The study evaluates whether inflammatory biomarkers can predict cognitive impairment in older Hispanic adults using interpretable machine learning on a small clinical dataset. A leakage‑safe Bernoulli/Categorical Naive Bayes model was trained on 165 participants from the Panama Aging Research Initiative, with continuous predictors discretized via supervised chi‑square and income treated categorically. The biomarker I‑309 (CCL1) emerged as the sole reliable incremental predictor, boosting ROC‑AUC from 0.630 to 0.740 and achieving statistically significant performance across repeated cross‑validation and random partitions.
arXiv:2502. 03484v3 Announce Type: replace-cross Abstract: Dementia encompasses a group of syndromes that impair cognitive functions such as memory, reasoning, and the ability to perform daily activities.
arXiv:2607. 11656v1 Announce Type: cross Abstract: Accurate diagnostic classification and disease-severity prediction for Alzheimer's disease are hampered by the incompleteness and heterogeneity of real-world clinical data.
arXiv:2610.10648v1 Announce Type: new Abstract: Alzheimer's disease prediction involves irregular visits, heterogeneous measurements and incomplete modalities. This study presents a multimodal multit...
arXiv:2606. 11794v1 Announce Type: cross Abstract: Neurodegenerative diseases such as Alzheimer's disease (AD) require accurate and scalable tools for assessing disease severity, yet current clinical staging remains time-intensive and prone to variability.
The paper presents a diagnostic framework for Alzheimer’s disease that uses the Large Brain Model (LaBraM), a foundation model pretrained on over 2,500 hours of EEG data, to generate high‑dimensional latent embeddings. These embeddings are fed into a non‑linear Random Forest classifier, achieving an ROC‑AUC of 89.36% ± 3.49%, PR AUC of 81.45% ± 4.43%, and Balanced Accuracy of 82.44% ± 4.34% in a subject‑independent 5‑fold cross‑validation setting, using only 8‑second EEG segments. Post‑hoc occlusion and neurophysiological alignment analyses confirm that the model captures clinically validated biomarkers such as occipital‑frontal Alpha and Theta rhythm degradation and correlates with cognitive performance and clinical severity.
arXiv:2609.22092v1 Announce Type: cross Abstract: Electroencephalography (EEG) is a low-cost and non-invasive signal source for dementia screening, yet existing EEG-based studies remain difficult to...
The paper addresses the challenge of within-class variation in Alzheimer’s Disease (AD) detection, where individuals with the same diagnosis can show differing levels of cognitive impairment. It introduces two methods—Soft Target Distillation (SoTD) and Instance-level Re-balancing (InRe)—that estimate sample-specific AD probabilities to better capture this heterogeneity. Experiments on the ADReSS and CU-MARVEL datasets demonstrate that these scores correlate with independent cognitive assessments and enhance AD detection performance.